Siuolman58 Posted - 3 days ago

$CPIX Looks and feels like we are building some momentum! Be it a a turtles pace!!!

lucas123451 Posted - 4 days ago

$CPIX FDA willbe gone Jan.

Zamasu_ Posted - 5 days ago

$ZONE - Looking like $CPIX before its low-float rally. Volume will be the key here. 🚦

cramly Posted - 6 days ago

$CPIX volume has been crazy lately, but with share repurchases and insider accumulation volume should be decreasing as total outstanding decreases. Looks like someone is building a significant short position. With a 12% borrow rate not sure I see what they see

Siuolman58 Posted - 6 days ago

$CPIX Lets get fired up! News gotta be comin!

green_going_up Posted - 1 week ago

$CPIX this study on Caldolor vs Ketorolac WILL be game-changing based on my conversations with physicians. Will become the new standard of care. https://www.prnewswire.com/news-releases/new-study-compares-caldolor-ibuprofen-injection-to-ketorolac-302296908.html

lucas123451 Posted - 1 week ago

$CPIX don't fall into valuation trap. This is a company run by MBAs. Ifetroban was discovered by BMS over 30 years ago. search BMS 180,291. Then BMS donated to a university. Somehow $CPIX got it in 2011 via CET, 13 years ago. Majority of clinical subjects were done by BMS. In the 13 years $CPIX tried Ifetroban in variety of trials, all failed. Now CET has something "new", from my understanding after the final try of Ifetroban, they are moving on to something new at CET. $CPIX need a phd or md as a CEO to run clinical trial. MBAs cannot do it

MicroCapValue Posted - 1 week ago

$CPIX funny how low the Company is valued given that most biotech companies that come and go never achieving an approved product just valued on potential for their pipeline but often carrying lofty valuations just on this potential. Meanwhile, $CPIX has several marketed specialty pharma products with good growth potential that should resume in 4Q24 through 2025 in addition to a potentially valuable pipeline in the form of ifetroban + CET programs for delirium and non-invasive detection of internal/GI bleeding. 3 ongoing company-sponsored studies for ifetroban with muscular dystrophy (DMD) being the major potential catalyst given FDA Orphan Drug + Rare Pediatric Disease designations with potential for valuable PRV if they get approved. Newest study is pulmonary fibrosis (IPF) also an Orphan indication they have yet to file. Systemic sclerosis the other likely trial they will conclude this year per guidance on Q3 updates to close 2 ifetroban studies, report data and decide on next steps.

MicroCapValue Posted - 1 week ago

$CPIX notes from 10-Q filing: - VIBATIV sales in 3Q24 only $1 million due to hurricane impact vs. $2.8 million in 3Q23 - if not for the hurricane impact on VIBATIV sales would have likely seen 3Q24 total revenue around $11 million, continuing double-digit sequential growth, which should resume when Q4 results are reported - $2.5 million remaining for share repurchase program with $0.5 million in shares repurchased first 9 months of 2023 & 2024 - through 3Q24 repurchased 275K shares at just over $1.80/share average, so should be purchasing shares again soon now that Q3 updates are out and they are free to resume share buybacks, especially with stock near all-time lows - Octapharma is partner for radiopharma imaging agent to detect internal GI bleeding by identifying blood clots as a non-invasive alternative to colonoscopy to visualize active bleeding - Octapharma will fund all development in exchange for paying milestones + royalties & they are preparing to file IND to begin clinical study

justiceforb_85 Posted - 1 week ago

$CPIX looks like ifetroban had been studied for other indications but now the company is aiming for indication in Duchenne Muscular Dystrophy-Associated Cardiomyopathy. Do we have any data for efficacy in any indication?

MicroCapValue Posted - 1 week ago

$CPIX a few more updates: - cash up slightly to $17.5 million from $17.3 million previous quarter - revolving line of credit debt remains at $16.1 million with initial limit of $20 million, maturity date of 10/1/26 and potential for increase to $25 million - ifetroban + CET pipeline all potential for bonus upside as currently marketed products performing well with likely return to double-digit sequential revenue growth with Q4 updates - HOPE-DMD trial a major potential catalyst due to potential for valuable priority review voucher that could be monetized for multiple of currently depressed market cap - even if the ifetroban trials fail, valuation is still way too low trading at just under 0.5X sales and just above 0.5X book value while most pharma companies trade at multiples of these metrics - we definitely need some more eyeballs here to increase liquidity and price but should come over time if they deliver on growth or if any of the pipeline hits or possibly a new product acquisition

MicroCapValue Posted - 2 weeks ago

$CPIX Q3 updates: - missed on sequential rev growth due to hurricane impact on VIBATIV sales but otherwise solid quarter with $9.1 million revenue - Q4 seasonally strongest quarter so should see return to double-digit sequential revenue growth with next update - will be completing HOPE-DMD + systemic sclerosis trials this quarter with results and development plans to follow - some interesting projects at CET for delirium and detecting internal bleeding proceeding to pivotal study and first-in-human trial, respectively, and the latter has corporate sponsor to fund development - VIBATIV about to launch in Saudi Arabia with China approval pending and CALDOLOR filed for approval in Mexico - granted FDA Orphan + Rare Pediatric Disease designations for ifetroban the latter of which could result in priority review voucher (PRV) if approved - PRVs typically sell for $70-100 million which equates to $5-7/share for $CPIX so HOPE-DMD results could be a major upside catalyst if positive

MoTownVol Posted - 2 weeks ago

$CPIX that was disappointing

miadams Posted - 2 weeks ago

$CPIX if i'm reading the 8k right, sancuso and caldolor had big revenue jumps and i think they're up 15% and 9% ytd yoy. i'm curious what the hurricane impact was to vibativ. did they say the number?

QLevel Posted - 2 weeks ago

$CPIX lotto position here

boy2roudy Posted - 2 weeks ago

$CPIX

Siuolman58 Posted - 2 weeks ago

$CPIX Good news tonight! Seller has left the party!

TheUnintelligetInvestor Posted - 2 weeks ago

$CPIX moving

osubuck30 Posted - 2 weeks ago

$CPIX for anyone new here the public float is under 8 million shares.

AI_TRADER_ Posted - 2 weeks ago

$CPIX

TheUnintelligetInvestor Posted - 2 weeks ago

$CPIX https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-receives-fda-orphan-drug-and-rare-pediatric-disease-designations-for-new-treatment-of-duchenne-muscular-dystrophy-302298060.html

Siuolman58 Posted - 2 weeks ago

$CPIX it’s comin! Just wait till someone is done playing!

TheUnintelligetInvestor Posted - 2 weeks ago

@beppels do you think $CPIX gets a move off last night’s phase 2 news? Surprised it didn’t get juiced.

TheUnintelligetInvestor Posted - 2 weeks ago

@Weatherman118 $cpix had phase 2 news last night

TheUnintelligetInvestor Posted - 2 weeks ago

@MS_Tammy $cpix had phase 2 news last night. Think it moves today?

AI_TRADER_ Posted - 2 weeks ago

$CPIX phase 2 🔞🔞🔞🔞🔞🔞

boy2roudy Posted - 2 weeks ago

$CPIX

boy2roudy Posted - 2 weeks ago

$CPIX $DRUG $NUWE $TVGN

boy2roudy Posted - 2 weeks ago

$CPIX $DRUG $TSLA $TVGN

boy2roudy Posted - 2 weeks ago

$CPIX